Dyne Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. The company's proprietary FORCE™ platform is engineered to overcome the historical limitations of delivering macromolecular therapeutics to muscle tissue and the central nervous system (CNS). By combining a monoclonal antibody that targets the transferrin receptor 1 (TfR1) with a linker and a disease-specific oligonucleotide payload, the FORCE platform is designed to enhance cellular uptake and target the genetic basis of diseases directly in skeletal, cardiac, and smooth muscle. Dyne's lead clinical programs include z-rostudirsen (formerly DYNE-251) for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping, and z-basivarsen (formerly DYNE-101) for myotonic dystrophy type 1 (DM1).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead clinical programs z-rostudirsen (DYNE-251) for DMD and z-basivarsen (DYNE-101) for DM1 toward regulatory approvals and commercial launches using the proprietary FORCE platform.
Expected impact: Establishes Dyne as a commercial-stage rare disease biopharmaceutical company with potentially best-in-class therapeutics.
Developing preclinical candidates including DYNE-302 for facioscapulohumeral muscular dystrophy (FSHD), DYNE-401 for Pompe disease, and programs for other DMD mutations.
Expected impact: Broadens the therapeutic reach of the FORCE platform beyond the two lead indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides exclusive rights to target the DUX4 gene, which is the genetic basis of facioscapulohumeral muscular dystrophy (FSHD), supporting the development of DYNE-302.
Terms: Not fully disclosed.